Ricardo Augusto Delfino1*, Fernando Jacobsen de Barros1, Rafael Mourae Sucupira1, Marcelo Gomes de Almeida1, Gil Patrus Mundim Pena2, Isabel Cristina Gomes3, Augusto Afonso Guerra4, Brian Godman5,6,7,8 and Alessandra Maciel Almeida9
1Department of Neurosurgery, Madre Teresa Hospital, Brazil
2Department of Neuropathology, Madre Teresa Hospital, Brazil
3Post Graduation Program in Health Sciences, Faculty of Medical Sciences of Minas Gerais (FCM-MG), Brazil
4Post Graduation Program in Medicines and Pharmaceutical Assistance, Federal University of Minas Gerais (UFMG), Brazil
5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
6Division of Public Health Pharmacy and Management, Sefako Makgatho Health Sciences University, South Africa
7Department of Laboratory Medicine, Karolinska Institute, Karolinska University, Sweden
8School of Pharmaceutical Sciences, University Sains Malaysia, Penang, Malaysia
9Post-Graduation Program in Health Sciences, Faculty of Medical Sciences of Minas Gerais (FCM-MG), Federal University of Minas Gerais (UFMG), Brazil
*Corresponding author:Ricardo Augusto Delfino, Department of Neurosurgery, Madre Teresa Hospital, Belo Horizonte, Minas Gerais, Brazil; Post-Graduation Program in Health Sciences- Faculty of Medical Sciences of Minas Gerais (FCMMG)
Submission: May 17, 2023;Published: May 31, 2023
ISSN 2637-7748Volume5 Issue3
Glioblastoma is the most frequent and aggressive primary malignant brain tumor in adults. It is considered a fatal disease, and the average survival time is approximately 12 to 18 months.
Objectives: Evaluate risk factors and the survival time in patients diagnosed with glioblastoma.
Materials and methods: A retrospective study was performed at a neurosurgery reference hospital in
Belo Horizonte, MG, Brazil observing patients who underwent glioblastoma surgery. From the electronic
medical records were collected the sociodemographic data, Karnofsky Performance Status (KPS), tumor
location and volume. Surgical specimens were evaluated according to protein expression using the Ki-67
index and the date of death was evaluated in the Mortality Information System.
Results: The sample consisted of 25 patients, most were male (52%) and 40% were older than 65 years;
76% of patients had a KPS index>80. The tumor location was predominantly frontal and temporal. Longer
mean survival observed among males, patients <65 years, Ki-67 index up to 20%, KPS > 80 and frontal
tumor location. A reduction in the risk of dying was observed in patients with a KPS > 80. Patients who
survived less than 12 months had a higher median Ki-67 index.
Conclusion: No statistically significant differences were found in the survival curves comparing a Ki-67
index up to 20 and Ki-67 index > 20 or the stratified Ki-67 index, however, higher risk of dying in older
patients with a Ki-67 index > 20.
Keywords: Glioblastoma; Ki-67; Immunohistochemistry; Survival
Get access to the full text of this article